Available Technologies


Project TitleGenetic polymorphism predicts clinical outcomes of colorectal cancer patients
Track Code2016-112
Short Description
Tagscolorectal cancer, irinotecan, oxaliplatin, clinical outcome marker, oncology
Posted DateMar 10, 2017 12:55 PM

Market Opportunity

Combination therapy with both irinotecan (CPT-11) and oxaliplatin (L-OHP) is an aggressive regimen that is prescribed for the treatment of colon cancer and is extremely toxic. Methods to select patients for either irinotecan or oxaliplatin therapy based on biomarkers for responsiveness would avoid administration of unnecessary treatment and mitigate toxicity. 

USC Solution

USC researchers have discovered that colorectal cancer patients harboring certain genotypes within a gene involved in the repair of DNA double-strand breaks (DSBs) are likely to experience more desirable clinical outcomes when treated with a therapy comprising either irinotecan or oxaliplatin. Desirable clinical outcomes include higher likelihood to respond to the therapy, longer progression-free survival (PFS), longer overall survival (OS), and milder or lower likelihood of adverse effects.

Value Proposition

  • Simple genotyping test
  • Ability to select patients more likely to respond to therapy
  • More desirable clinical outcomes


  • Colorectal cancer treatment
  • Selection of patients for irinotecan or oxaliplatintherapy

Stage of Development

  • Clinical study involving more than 600 patients in three different cohorts

Intellectual Property


Patent pending

Key Publication:

Publication pending

Contact Information

Camilo Ansarah-Sobrinho, Licensing Associate, Life Sciences

USC Stevens Center for Innovation

(213) 821-6071



File Name Description
NCD 2016-112 - Genetic polymorphism predicts clinical outcomes of colorectal cancer patients.pdf None Download